Latest News - Page 2 of 49 - Oklahoma Society of Clinical Oncology

Bristol Myers Squibb announces FDA approval for Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

Bristol Myers Squibb (NYSE: BMY) recently announced that Opdivo®(nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon the existing adjuvant indication for Opdivo and further reinforcing the company’s legacy of providing treatment options for […]

Read More

AstraZeneca shares the latest overall survival (OS) data for IMFINZI® in combination with IMJUDO®

AstraZeneca recently shared the latest overall survival (OS) data for IMFINZI® (durvalumab) in combination with IMJUDO®(tremelimumab-actl) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).1,2  Primary AnalysisThe primary analysis demonstrated statistically significant improvement in the primary endpoint of OS vs sorafenib in the first-line (1L) treatment of uHCC1,2: *The HR is based on the stratified Cox proportional hazards […]

Read More

Takeda Provides Update on EXKIVITY® (mobocertinib)

Takeda has announced that following discussions with the U.S. Food and Drug Administration (FDA), we will begin the process of voluntarily withdrawing EXKIVITY (mobocertinib) from the U.S. market over the next few months. EXKIVITY is currently indicated for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small […]

Read More

Pfizer Oncology announces FDA approval of ELREXFIO™ (elranatamab-bcmm).  

The following information is available for State Society review:  §  Full Prescribing Information Including Boxed Warning and Medication Guide 

Read More

New Data for TAGRISSO® (osimertinib) in the ADAURA Trial

AstraZeneca recently announced that new data from the ADAURA trial regarding AGRISSO® (osimertinib) has been released. The ADAURA trial is an ongoing study of TAGRISSO as adjuvant therapy after tumor resection in adult patients with completely resected Stage IB-IIIA EGFRm (exon 19 deletions or exon 21 L858R mutations) non-small cell lung cancer (NSCLC). TAGRISSO was approved as […]

Read More

New FDA Approved Indication for LYNPARZA® (olaparib)

AstraZeneca recently announced that the US Food and Drug Administration (FDA) has approved a new indication for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA. […]

Read More

Seagen Announces FDA Accelerated Approval of TUKYSA®

Top of Form Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer – First FDA-approved treatment in HER2-positive metastatic colorectal cancer – – Combination regimen is approved for use in the second-line treatment setting and beyond – BOTHELL, Wash.–(BUSINESS WIRE)– Seagen Inc. (Nasdaq: […]

Read More

Merck announces new treatment indication for KEYTRUDA®

Merck announces new treatment indication for KEYTRUDA® Adjuvant Treatment Following Resection and Platinum-Based Chemotherapy for Adult Patients With Stage IB (T2a ≥4 cm), II, or IIIA NSCLC KEYTRUDA® (pembrolizumab) Injection 100 mg, as a single agent, is indicated for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), […]

Read More

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer

Coverage to include serial monitoring in all subtypes, including hormone receptor-positive, HER2-positive, and triple negative breast cancers Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that it has received written confirmation from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) that Natera’s Signatera molecular residual disease (MRD) […]

Read More

Pharmacyclics LLC, an AbbVie company, will host a presentation on IMBRUVICA® (ibrutinib) during the ASH Annual Meeting.

Pharmacyclics LLC, invites you to attend a Multidisciplinary Discussion during the 2022 ASH Annual Meeting on Incorporating Imbruvica® (ibrutinib) into treatment strategies.   The program will be held on Monday December 12th from 8:00 to 9:00 AM in Exhibit Hall/Theater 7 during the ASH Annual Meeting.  Session sponsored by Pharmacyclics LLC, an AbbVie company and […]

Read More